Science, Statistics and Decisions - The Right Questions and the Best Answers

Download Presentations

Welcome! Contact Kathleen Wert if you are experiencing difficulties accessing the presentations.


General Session I: The Agency's Critical Path Initiative and the Statistician's Role in Evaluating the Safety of New Drug Products

No presentations received

General Session II: Flexible Design: A Debate
Powerpoint Format Presentation A - Bayesian Adaptive Design & Interim Analysis - Donald Berry
General Session III: Non-inferiority Trials: What Are Our Experiences?
PDF Format Presentation B - Non-Inferiority in Conformity Active Control Clinical Trials: Concepts and Statistical Methods - Gary Koch
General Session IV: Quantifying the Ratio of Risk and Benefit - no presentations received
Powerpoint Format Presentation B - Superior Safety in Noninferiority Trials- David R. Bristol
Parallel Sessions I - Gate-keeping Strategy, Co-primary Endpoints and Secondary Endpoints
Powerpoint Format Presentation A - Multiplicity Adjustment for Clinical Trials with Two Doses of an Active Treatment and Multiple Primary and Secondary Endpoints - Hui Quan
Powerpoint Format Presentation B - Gatekeeping Testing Strategies in Clinical Trials - Alex Dmitrienko
Powerpoint Format Presentation C - On Some Statistical Considerations in Testing for Multiple Endpoints in Clinical Trials - Mohammad Huque
PDF Format Presentation D - Discussion for 'Gate-Keeping Strategy Session" - Gary Koch
Parallel Sessions II - Evolving Data Standards: Implications for Statistical Analysis and Review
Powerpoint Format Presentation A - Evolving Data Standards: Implications for Statistical Analysis and Review - Stephen Ruberg
Powerpoint Format Presentation B - Beyond the CDISC SDTM V3.1 Model: Statistical & Programming Considerations - William Qubeck
Parallel Sessions III - Controls
PDF Format Presentation A - Controls from Principal Stratification and an example from the Baltimore's Needle Exchange Program - Constantine Frangakis
Powerpoint Format Presentation B - Using an External Control to Evaluate the Effectiveness of Posaconazole for Refactory Invasive Fungal Infections - Kenneth Koury and Jagadish P. Gogate
Powerpoint Format Presentation C - The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective - Lilly Yue
Parallel Sessions IV - Missing Data: Are We Dealing With the Real Problem?
Powerpoint Format Presentation A - Comparing LOCF with mixed-model analysis (MMRM) for longitudinal trials with missing data - Peter Lane
Powerpoint Format Presentation B - Sensitivity Analysis for Randomized Trials with Missing Data - Daniel Scharfstein
Powerpoint Format Presentation C - Management of Missing Data in Clinical Trials from a Regulatory Perspective - James Hung
Parallel Sessions V - Advisory Committees and Regulatory Review

No presentations received

Parallel Sessions VI - Surrogate Markers in Drug Development
Powerpoint Format Presentation A - Surrogate Markers and its Role in the Drug Development Process - Aloka Chakravarty
Powerpoint Format Presentation B - Statistical Challenges in the Validation of Surrogate Endpoints - Marc Buyse
Powerpoint Format Presentation C - Statistical Issues in the Validation of Surrogate Endpoints - Stuart Baker
Powerpoint Format Presentation D - Promotion and Marketing of Prescription Drugs - Lesley R. Frank
Powerpoint Format Presentation E - A Practical Approach to Accelerating the Clinical Development Process - Jerald S. Schindler
Parallel Sessions VII - Accelerating Drug Development Using Novel Experimental Designs and Analyses
Powerpoint Format Presentation A - A Practical Approach to Accelerating the Clinical Development Process - Jerald S. Schindler
Parallel Sessions VIII - Issues in Phase IV Post Marketing and Production
No presentations received
Parallel Sessions IX - FDA/Industry Symposium on Clinical Pharmacogenomics/Proteomics
No presentations received